Overview
The marketing authorisation for Doxirobe has not been renewed by the marketing authorisation holder and is now withdrawn.
Authorisation details
| Product details | |
|---|---|
| Name |
Doxirobe
|
| Agency product number |
EMEA/V/C/000044
|
| Active substance |
doxycycline
|
| International non-proprietary name (INN) or common name |
Doxycycline
|
| Species |
Dogs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QJ01AA02
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Pfizer Limited
|
| Revision |
4
|
| Date of issue of marketing authorisation valid throughout the European Union |
16/09/1999
|
| Contact address |
Ramsgate Road
Sandwich Kent CT13 9NJ United Kingdom |
Product information
01/12/2003 Doxirobe - EMEA/V/C/000044 -
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antibacterials for systemic use
Therapeutic indication
Treatment of periodontal disease in dogs.
Periodontal pocket probing depths >=4 mm are evidence of disease that may be responsive to treatment with the Doxirobe Gel. Use of this product as directed should result in attachment level gains, periodontal pocket depth reductions, local antimicrobial effect and improved gingival health. Noticeable improvements in these parameters should be evident within 2-4 weeks following treatment. The response in individual dogs is dependent on the severity of the condition and rigor of adjunctive therapy.